Twist Bioscience Stock Fair Value – Twist Bioscience receives “Moderate Buy” recommendation from top brokerages for its shares

☀️Trending News

Twist Bioscience ($NASDAQ:TWST) is a leading synthetic biology company that specializes in producing high-quality synthetic DNA for a variety of applications. The company’s stock has been gaining attention from top brokerages in recent months, with several of them giving the company a “Moderate Buy” recommendation for its shares. According to recent reports, nine brokerages have provided an average “Moderate Buy” recommendation for Twist Bioscience’s stock, highlighting the potential growth and value of the company’s shares. This is a promising sign for investors, as it shows that these top brokerages believe in the company’s future prospects and are confident in its ability to deliver returns. One factor that may be contributing to the positive outlook for Twist Bioscience is the growing demand for synthetic DNA in various industries. The company’s unique technology platform allows for the rapid production of high-quality, custom-designed DNA, making it a valuable partner for companies in industries such as biotechnology, pharmaceuticals, and agriculture. As these industries continue to grow and evolve, Twist Bioscience is well-positioned to benefit from the increasing need for synthetic DNA. Additionally, Twist Bioscience has been making strategic partnerships and collaborations to further enhance its offerings and expand its market reach. For example, the company recently announced a collaboration with Ginkgo Bioworks to produce DNA-based data storage solutions and another partnership with Illumina to develop a custom sequencing solution. These partnerships not only showcase Twist Bioscience’s innovative capabilities but also open up new opportunities for revenue growth. Of course, as with any investment, there are always potential risks and uncertainties to consider. The biotech industry can be volatile, and competition is fierce.

However, with Twist Bioscience’s strong technology platform, growing demand for its products, and strategic partnerships in place, many top brokerages believe that the company’s shares have the potential for significant growth. With its unique technology, expanding partnerships, and increasing demand for synthetic DNA, Twist Bioscience is certainly a stock to watch in the biotech industry.

Market Price

This news sent a positive ripple through the market, with the company’s stock opening at $40.53 and closing at $40.57 – a 0.82% increase from the previous day’s closing price of $40.24. This recommendation comes as no surprise, considering Twist Bioscience‘s strong performance in the biotech industry. The company specializes in DNA synthesis, a critical aspect of genetic research and drug development. With its cutting-edge technology and innovative approach, Twist Bioscience has already made significant contributions to the field of biotechnology. This rating is given when a stock is expected to perform slightly better than the market average, making it an attractive investment option for investors. It reflects the confidence of these brokerages in Twist Bioscience’s growth potential and supports their belief that the company’s shares are undervalued.

Investors have taken note of this recommendation, and it is evident in the positive movement of Twist Bioscience’s stock. This news also highlights the increasing interest in biotech companies and their potential for growth and profitability. With continued advancements in genetic research and drug development, Twist Bioscience is well-positioned to capitalize on the growing demand for its services. As it continues to make strides in DNA synthesis and gain recognition in the biotech industry, investors can expect to see positive movements in its stock price. With its innovative approach and strong performance, Twist Bioscience is a company to watch out for in the biotech sector. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Twist Bioscience. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Twist Bioscience. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Twist Bioscience. More…

Key Ratios Snapshot

Some of the financial key ratios for Twist Bioscience are shown below. More…

Analysis – Twist Bioscience Stock Fair Value

After conducting a thorough analysis of TWIST BIOSCIENCE, I have determined that the fundamentals of this company are strong. TWIST BIOSCIENCE is a leading provider of synthetic DNA and gene editing technology, which is in high demand in the biotechnology industry. Based on my proprietary Valuation Line, I have calculated that the fair value of TWIST BIOSCIENCE shares is around $78.7. This indicates that the stock is currently undervalued by approximately 48.4%, as it is currently trading at $40.57. One factor contributing to this undervaluation could be the recent market volatility and uncertainty surrounding the biotechnology sector. However, considering TWIST BIOSCIENCE’s strong fundamentals and its position as a market leader in its field, I believe that the stock has significant potential for growth in the long-term. In addition, TWIST BIOSCIENCE has a solid financial standing, with a strong balance sheet and steady revenue growth. The company has also formed strategic partnerships with major players in the biotech industry, further strengthening its position in the market. Overall, I am confident in the long-term prospects of TWIST BIOSCIENCE and believe that at its current undervalued price, it presents a great investment opportunity for investors looking to capitalize on the growing demand for synthetic DNA and gene editing technology. More…

Peers

It offers DNA synthesis on a silicon chip, which enables the company to offer its services at a lower cost than its competitors. The company’s competitors include HTG Molecular Diagnostics Inc, Proteome Sciences PLC, and Genedrive PLC.

– HTG Molecular Diagnostics Inc ($NASDAQ:HTGM)

FoundHTG’s cutting-edge molecular diagnostic platform and cancer test portfolio offers clinicians actionable insights to improve patient outcomes. The company’s tests are designed to guide precision cancer treatment decisions by identifying the specific genetic alterations that drive a patient’s tumor.

FoundHTG’s products are available through a global network of distributors and partners. The company’s tests are used in more than 30 countries and have been validated in over 1,000 peer-reviewed publications.

FoundHTG has a market cap of $6.07M and a ROE of -156.17%.

– Proteome Sciences PLC ($LSE:PRM)

Proteome Sciences PLC is a United Kingdom-based company, which is engaged in the business of proteomics. The Company’s primary focus is on the development and application of proteomics technologies for the biomarker discovery, validation and protein profiling across a range of life science research and clinical applications. It operates through two segments: Biomarkers and Protein Analysis. The Biomarkers segment includes the development and commercialization of biomarkers for diagnostics and drug development. The Protein Analysis segment provides contract research services to the pharmaceutical, biotechnology and academic sectors.

– Genedrive PLC ($LSE:GDR)

Genedrive PLC is a molecular diagnostics company. The Company focuses on the development and commercialization of its technology for the diagnosis of infectious diseases and point-of-care testing. It operates through the following segments: Genedrive and Genedrive Asia Pacific. The Genedrive segment comprises the Company’s operations in Europe, the Middle East, Africa and the Americas. The Genedrive Asia Pacific segment comprises the Company’s operations in Asia Pacific.

Summary

Investment analysis of Twist Bioscience Co. shows that the stock has received a “Moderate Buy” recommendation from nine brokerages. This indicates that the company is expected to perform well in the near future. Investors may want to consider buying shares of Twist Bioscience as it is likely to see positive growth and potential returns. The company’s strong financials and promising products make it an attractive investment opportunity.

However, investors should also carefully assess its risks and market conditions before making any decisions. Overall, Twist Bioscience seems to be a promising investment option with a positive outlook from analysts.